Nektar Therapeutics (NKTR.OQ)
84.51USD
24 Apr 2018
$-0.94 (-1.10%)
$85.45
$86.14
$87.00
$83.11
648,439
1,070,862
$111.36
$17.33
About
Overall
| Beta: | 1.38 |
| Market Cap(Mil.): | $3,878.49 |
| Shares Outstanding(Mil.): | 156.33 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NKTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.02 | 32.74 |
| EPS (TTM): | -1.40 | -- | -- |
| ROI: | -53.15 | 1.58 | 14.38 |
| ROE: | -- | 2.41 | 16.07 |
BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS
BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21
* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:
Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion(1.33 billion pounds) for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.
Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.
UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar
Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.
Bristol-Myers to pay $1.85 bln in cancer deal with Nektar
Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.
BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement
* NEKTAR THERAPEUTICS - ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007 Source text: (http://bit.ly/2BsgSdG) Further company coverage:
BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement
* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018
BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program
* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs
BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald
* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN Source text (http://bit.ly/2zxBcXv) Further company coverage:
Competitors
| Price | Chg | |
|---|---|---|
| Takeda Pharmaceutical Co Ltd (4502.T) | ¥4,550 | -301.00 |
| Eisai Co., Ltd (4523.T) | ¥7,376 | +238.00 |
| NOF CORPORATION (4403.T) | ¥3,210 | 0.00 |
| Dr.Reddy's Laboratories Ltd (REDY.NS) | Rs2,135.70 | -14.45 |
| Novo Nordisk A/S (NOVOb.CO) | kr.288.65 | -- |
| Pfizer Inc. (PFE.N) | $37.06 | +0.26 |
| Novartis AG (NOVN.S) | CHF75.76 | -- |
| Roche Holding Ltd. (ROG.S) | CHF219.20 | -- |
| Roche Holding Ltd. (RO.S) | CHF223.80 | -- |
| GlaxoSmithKline plc (GSK.L) | 1,462.20 | -- |
Estimates